Cardio Diagnostics Holdings, Inc. released its full year 2024 financial results, reporting a net loss of US$8.38 million. This net loss remained flat compared to the prior fiscal year, indicating a consistent level of operational investment.
While the company's Earnings Per Share (EPS) reportedly beat expectations, revenues lagged behind projections. This mixed financial performance highlights the ongoing challenges of an early-stage biotechnology company focused on growth and market penetration.
The continued net loss underscores the company's reliance on external financing to fund its operations and growth initiatives. Investors will closely monitor future reports for signs of revenue acceleration and progress towards profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.